Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

This phase Ib trial tests the safety, side effects and how well losartan, pembrolizumab and stereotactic body radiation therapy (SBRT) for the treatment of patients with head and neck squamous cell carcinoma that has come back to nearby tissue or lymph node after a period of improvement (locally recurrent), that has not responded to previous treatment (refractory) or that has spread from where it first started to multiple other placed in the body (oligometastatic). Losartan is a drug used to treat high blood pressure that may enhance the effects of other cancer treatments such as immunotherapy

Trial Details

NCT ID
NCT06211335
Phase
PHASE1
Sponsor
University of California, Davis
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Losartan
  • Pembrolizumab
  • Stereotactic Body Radiation Therapy
Locations (sample)
  • Sacramento, California, United States|38.58157,-121.4944
  • Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

  • Histologically or cytologically confirmed locoregionally recurrent, refractory, or oligometastatic (at most 4 lesions) squamous cell carcinoma of t…
  • p16 status known for base of tongue, soft palate, and tonsil cancers
  • Tumor amenable to sequential biopsies, and patients willing to undergo sequential tumor biopsies so long as the treating investigator considers the…
  • Prior radiotherapy to the head and neck is allowed. Disease should be limited to up to 4 sites of active disease in the head and neck and/or distan…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →